مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

الدراسة الإستقصائية للمستشفيات الوطنية

Process
  • All hospitals that are contracted to the MOPH for treatment of MOPH patients in 2001will be included in the First National Hospital Survey and the main purpose is to assess all contracted hospitals against the Basic and Accreditation standards, for bench marking purposes.
  • The First National Hospital Survey will be undertaken by the OPCV Project Team under the supervision of the Ministry of Public Health (MOPH) and the Health Sector Rehabilitation Project (HSRP). The Project is financed by the World Bank.
 
Resources
  • The attached forms cover all acute hospital Departments/ Services for Basic and Accreditation standards.
  • The forms should be considered in conjunction with the relevant section of the (a) Hospital Accreditation Manual, and (b) Guidelines. Both these publications are included in the kit.
  • The forms will be used by the visiting Hospital Survey Team to assess each Department/Service of your hospital against the standards.
  • Your hospital may utilise these forms in your preparation for the survey, by photocopying as many as required for self-assessment purposes. However, in the First National Hospital Survey your self-assessment is not included as a part of the official result.
 
Survey
  • A schedule of visits by the Survey Teams is currently being compiled. It is vitally important that once the survey dates are arranged that your hospital does not alter the dates. There are some 134 hospitals involved in the survey that will take place over a 12 month period. Any hospitals reneging on the survey dates without very advanced negotiation will either go to the back of the queue or be relegated from the survey altogether. Your cooperation in regard to the scheduling is crucial to the success of the exercise.
  • For the majority of hospital surveys there will be three surveyors per team, consisting of a general hospital Administrator, a Nurse with clinical and administrative experience, and a Physician with clinical and administrative experience. There will be an extra clinical team member for hospitals over 150 beds in total.
  • For some surveys there will be an observer with the team. This will be a person from either the MOPH or the HSRP. The observer will be undergoing training as a surveyor through the OPCV so that skills can be transferred for future surveys in Lebanon. The observer will not have any executive, advisory or reporting responsibilities during his/her training period with OPCV. All aspects of confidentiality in regard to individual hospital information and results will be respected.
  • The survey team will be on site at the hospital for a varying number of days depending on hospital size in terms of total bed numbers as per official MOPH lists:
 
Hospital size On site survey days
49 beds or less One day (1)
50-99 beds Two days (2)
100-149 beds Two days (2)
150 + beds Three Days (3)
 
 
Scoring
The scoring system to be used for surveys will be as follows:
Basic standards Yes: One point
No: Zero points
Not Applicable: Excluded from calculation
Accreditation standards Yes: One point
No: Zero points
Needs improvement: 0.5 points
Not applicable: Excluded from calculation
 
  • Needs improvement.This category has been developed for the Accreditation standards so that the survey team can allot some credit where the hospital is making demonstrated progress on a particular standard. The category is not used for the Basic standards because these are lower level standards that are expected to be fully implemented
  • The Survey Team will calculate the Department/ Service results, and the overall result and advise the MOPH and your hospital at the completion of the First National Hospital Survey. All hospitals will be measured against both the Basic and the Accreditation standards
 
Results
  • The overall percentage required for the various assessments are:
% Basic % Accreditation Result Acronym
85% Basic Standards  65% + Accreditation Standards Full Accreditation Status  BFA
65% - 84% Basic Standards 65% + Accreditation Standards Partial Accreditation Status  BPA
65% + Basic Standards < 65% Accreditation Standards No Accreditation Award but passed Basic  BNA
50% - 64% Basic Standards < 65% Accreditation Standards No Accreditation award, Partial pass on Basic  PB
< 50% Basic Standards < 65% Accreditation Standards No Accreditation Award and Failed on Basic Standards NB
 
  • After the on site visit the OPCV Team will be involved in writing up the survey in the OPCV office. A detailed survey assessment report will be completed and Forworded to the MOPH and your Hospital.
  • During the First National Hospital Survey the opportunity will also be taken by the OPCV Team to recommend any changes to the Hospital Accreditation Manual and/or the processes adopted for surveys.
  • Beyond that there will be an interim period in which hospitals can prepare for actual Accreditation Assessment, based on the Survey results.
 
Further Contact
Please contact the OPCV Team Leader or the HSRP if you have any comments or queries about this Accreditation Survey Kit:
  • OPCV: Telephone 1 747 263/64
  • HSRP: Telephone 1 616 601 Mr. Roy Wakim
 
    1
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم ↑
J06BA02 KIOVIG BioHuman Human normal immunoglobulin G - 5g/50ml 5g/50ml Injectable solution 35,639,835 L.L
J06BA02 KIOVIG BioHuman Human normal immunoglobulin G - 10g/100ml 10g/100ml Injectable solution 54,343,313 L.L
N03AX14 KEPAM MS G Levetiracetam - 500mg/5ml 500mg/5ml Injectable solution 9,170,015 L.L
D07AC13 KONEX G Mometasone furoate - 0.1% 0.1% Solution 385,683 L.L
J01CR02 KLAVOX G Amoxicillin (trihydrate) - 400mg/5ml, Clavulanic Acid (potassium) - 57mg/5ml 457mg/5ml Powder for suspension 278,175 L.L
B02BA01 KONAKION MM PEDIATRIC B Phytomenadione - 2mg/0.2ml 2mg/0.2ml Solution 442,124 L.L
J01CR02 KLAVOX G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet, film coated 338,648 L.L
L01EF02 KISQALI B Ribociclib - 200mg 200mg Tablet, film coated 200,752,977 L.L
M01AE03 KETOPROFENE MACOPHARMA G Ketoprofen - 100mg/100ml 100mg/100ml Injectable solution 329,241 L.L
D10AD01 KETREL G Tretinoin - 0.05% 0.05% Cream 397,777 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 25mg 25mg Tablet, film coated 399,121 L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 250mg/5ml 250mg/5ml Granules for suspension 477,384 L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 500mg 500mg Capsule 659,123 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 50mg/2ml 50mg/2ml Injectable concentrated solution 435,405 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 50mg/2ml 50mg/2ml Injectable solution 435,405 L.L
J06BA02 KIOVIG BioHuman Human normal immunoglobulin G - 5g/50ml 5g/50ml Injectable solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution L.L
L01FF02 KEYTRUDA BioTech Pembrolizumab - 100mg/4ml 100mg/4ml Injectable solution L.L
L01XG02 KYPROLIS B Carfilzomib - 60mg 60mg Injectable powder for solution L.L
J01MA17 KINODROX B Prulifloxacin - 600mg 600mg Tablet, film coated 1,407,835 L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution 96,542,598 L.L
N02BE01 KIDOL-OR G Paracetamol - 240mg/5ml 240mg/5ml Elixir 314,843 L.L
C07AB05 KERLONE B Betaxolol HCl - 20mg 20mg Tablet, film coated, scored 575,165 L.L
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution 135,545,977 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution 216,872,714 L.L
L01FF02 KEYTRUDA BioTech Pembrolizumab - 100mg/4ml 100mg/4ml Injectable solution 241,744,802 L.L
D01AC08 KETOCONAZOLE KORHISPANA G Ketoconazole - 2% 2% Gel 599,354 L.L
L01XA02 KARBOTEEN G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 2,080,268 L.L
    1
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025